Author/Authors :
Shahzad، نويسنده , , Mian M.K. and Shin، نويسنده , , Yong-Hyun and Matsuo، نويسنده , , Koji and Lu، نويسنده , , Chunhua and Nishimura، نويسنده , , Masato and Shen، نويسنده , , De-Yo and Kang، نويسنده , , Yu and Hu، نويسنده , , Wei and Mora، نويسنده , , Edna M. and Rodriguez-Aguayo، نويسنده , , Cristian and Kapur، نويسنده , , Arvinder and Bottsford-Miller، نويسنده , , Justin and Lopez-Berestein، نويسنده , , Gabriel and Rajkovic، نويسنده , , Aleksandar and Sood، نويسنده , , Anil K.، نويسنده ,
Abstract :
The present study was undertaken to determine the expression and biological significance of HORMAD1 in human epithelial ovarian carcinoma. We found that a substantial proportion of human epithelial ovarian cancers expressed HORMAD1. In vitro, HORMAD1 siRNA enhanced docetaxel induced apoptosis and substantially reduced the invasive and migratory potential of ovarian cancer cells (2774). In vivo, HORMAD1 siRNA-DOPC treatment resulted in reduced tumor weight, which was further enhanced in combination with cisplatin. HORMAD1 gene silencing resulted in significantly reduced VEGF protein levels and microvessel density compared to controls. Our data suggest that HORMAD1 may be an important therapeutic target.
Keywords :
HORMAD1 , Ovarian cancer , Xenograft , Angiogenesis , VEGF
